A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 1, 2005, Pages 65-69

  Gupta, Supriya ^a   Mauer, Ann M ^a   Ryan, Christopher W ^a   Taber, David A ^b   Samuels, Brian L ^c   Fleming, Gini F ^a,d  

^a UNIVERSITY OF CHICAGO   (United States)

^b Michiana Hematology/Oncology   (United States)

^c ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Elderly; Phase II; Toxicity; UFT

Indexed keywords

FOLINATE CALCIUM; ORZEL; UFT;

ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDICATION; DRUG SAFETY; DYSGEUSIA; ELDERLY CARE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; INFECTION; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROTHROMBIN TIME; QT PROLONGATION; RESPIRATORY TRACT DISEASE; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG COMBINATIONS; FEMALE; HUMANS; LEUCOVORIN; TEGAFUR; URACIL;

EID: 13444272948     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000139020.58780.de     Document Type: Article

References (37)

1. Yancik R. Epidemiology of cancer in the elderly. Current status and projections for the future. Rays. 1997;22:3-9.
2. Britton LA, Devesa SS. Incidence, demographics and environmental factors. In: Harris JR, Lippman ME, Morrow M, et al. Diseases of the Breast. Philadelphia: Lippincott-Raven; 1996:159.
3. Meropol NJ, Rustum YM, Petrelli NJ, et al. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol. 1996;37:581-586.
4. Martin M, Casado A, Macias JA, et al. Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: a phase II study. Am J Clin Oncol. 2000;23:617-621.
5. Richardet E, Pedraza C, Mickiewicz E, et al. Uracil/tegafur plus oral calcium folinate in advanced breast cancer. Oncology (Huntingt). 1999; 13:96-97.
6. Repetto L, Pietropaolo M, Aapro M. Chemotherapy in the elderly with breast cancer. Forum. 2002;23:64-70.
7. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet. 1990;335:1020-1022.
8. Wyld L. Reed MW. The need for targeted research into breast cancer in the elderly. Br J Surg. 2003;90:388-399.
9. Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience. JAMA. 1992;268:57-62.
10. Ibrahim NK, Frye DK, Buzdar AU, et al. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996;156:882-888.
11. Giovanazzi-Bannon S, Rademaker A, Lai G, et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center Study. J Clin Oncol. 1994;12:2447-2452.
12. Zalcberg J, Kerr D, Seymour L, et al. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer. 1998;34:1871-1875.
13. Abad A, Navarro M, Sastre J, et al. A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group). Oncology. 1997;11:53-57.
14. Mani S, Sciortino D, Samuels B, et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs. 1999;17:97-101.
15. Mani S, Kugler JW, Sciortino DF, et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol. 1998; 9:1035-1037.
16. Mani S, Schiano T, Garcia JC, et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma. Invest New Drugs. 1998-99;16:279-283.
17. Feliu J, Gonzalez Baron M, Espinosa E, et al. Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Cancer. 1997;79:1884-1889.
18. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a Large Scale Phase III Trial. Cancer. 1995;75:11-17.
19. Sloan JA, Loprinzi CL, Novotny PJ, et al. Sex differences in fluorouracil-induced stomatitis. J Clin Oncol. 2000;18:412-420.
20. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;20:1491-1498.
21. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091-1097.
22. Fata F, Mirza A, Wood GC, et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma. Cancer. 2002; 94:1931-1938.
23. Meta-analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer. Effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16:3537-3541.
24. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994;12:2248-2253.
25. Port RE, Daniel B, Ding RW, et al. Relative importance of dose, body surface area, sex, and age for 5- fluorouracil clearance. Oncology. 1991;48:277-281.
26. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10:1171-1175.
27. Etienne MC, Chatelut E, Pivot X, et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer. 1998;34:92-97.
28. Petrelli N, Couglass HD, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol. 1991;7:1419-1426.
29. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol. 1994;12:14-20.
30. Cassidy J, Dirix L, Bissett D, et al. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable tumors. Clin Cancer Res. 1998;4:2755-2761.
31. Ichikura T, Tomimatsu S, Okusa Y, et al. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer. Cancer Chemother Pharmacol. 1996;38:401-405.
32. Sulkes A, Benner SE, Canetta RM. Uracil-ftorafur. An oral fluoropyrimidine active in colorectal cancer. J Clin Oncol. 1998;16:3461-3475.
33. Smith R, Wickerham DL, Wieand HS, et al. UFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer. Oncology (Huntingt). 1999;13(suppl 3):44-47.
34. Muggia FM, Wu X, Spicer D, et al. Phase I and pharmokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res. 1996;2:1461-1467.
35. O'Shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase II study of Xeloda (capecitabine) versus CMF as first line chemotherapy of breast cancer in women ≥55 years. Proc Am Soc Clin Oncol. 1998;17: 103a.
36. O'Shaughnessy J. Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function. Ann Oncol. 2002;6:983.
37. O'Shaughnessy J, Blum J. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc Am Soc Clin Oncol. 2000;19:104a.